바이오로직스 자료
Recognizing β-glucan impurities in biopharmaceuticals
β-glucan process-related impurities can be introduced into biopharmaceutical products and can cause false-positive results. In this webinar, Soonbin Kwon, a senior scientist in MSAT, shares his insights on how to tackle this issue and which downstream processes can reduce β-glucan.
β-glucan process-related impurities can be introduced into biopharmaceutical products and can cause false-positive results. In this webinar, Soonbin Kwon, a senior scientist in MSAT, shares his insights on how to tackle this issue and which downstream processes can reduce β-glucan.